Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.